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Pretreatment with divided doses of steroids strongly decreases side
effects of OKT3. The aim of this study was to attenuate side effects of
OKT3 by variation of the time interval between administration of corti-
costeroids and OKT3 in renal allograft recipients. In view of a maximal
lymphocytopenia at six hours following MPNS, we postulated a greater
preventive action on side effects from administration of methylpred-
nisolone (MPNS) at six hours preceding the first dose of OKT3 compared
to administration immediately before, Two groups of renal transplant
patients treated for acute rejection with 5 mg OKT3 were studied. Ten
patients received 500 mg MPNS six hours and ten patients one hour
before administration of OKT3. We measured clinical side effects, body
temperature, TNF and IL-6. There were no differences between the two
groups regarding clinical side effects and peak body temperatures. How-
ever, MPNS administered six hours before administration of OKT3
diminished TNF release; MPNS one hour before decreased IL-6 release.
We studied an additional group of six patients receiving 250 mg MPNS six
hours before, followed by 250 mg one hour before OKT3. This group
experienced significantly less side effects and lower body temperature. In
addition, IL-6 levels were significantly decreased. We conclude that two
times 250 mg MPNS administered six hours and one hour before the first
administration of OKT3 effectively attenuates adverse reactions following
administration of OKT3.
OKT3, a murine monoclonal IgG2a antibody (inAb) directed
against the TCR-CD3 complex on T lymphocytes, has proven its
efficacy in the prevention and treatment of allograft rejection
[1—4]. Expanded clinical application, such as in the treatment of
autoimmune diseases, may next be considered. However, the first
dose of this mAb is almost invariably followed by chills, fever,
dyspnea, headaches and gastrointestinal symptoms [5]. Data in
the literature show a relationship between these adverse reactions
and the appearance of circulating cytokines, that is, TNF, IFN-'y,
IL-2, IL-3 and IL-6 [6—11]. These cytokines are thought to be
released due to activation of mononuclear cells. In addition,
administration of OKT3 induces complement activation via the
classical pathway. Both cytokine release and complement activa-
tion leads to activation of granulocytes and sequestration of these
cells in the lungs, which may explain respiratory side effects [12].
To diminish adverse reactions, the manufacturer recommends the
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first administration of OKT3 to be preceded by an intravenous
bolus of corticosteroids. Corticosteroids are known to abrogate
both systemic reactions as well as peak levels of TNF and IFN-y
following administration of anti-CD3 mAb in mice [13, 14] and in
humans [6, 9, 15, 16]. Several of these authors suggest that not
only the administered dose of corticosteroids is important in
preventing systemic side effects, but also the time interval in
between the administration of steroids and the mAb [9, 13, 14,
15]. Gaston et al demonstrated a positive correlation between the
absolute number of circulating CD3 + and CD4 cells present
before therapy and the degree of clinical side effects [10]. Corti-
costeroids induce lymphocytopenia with a nadir at six hours
following administration [17—20]. We hypothesized that the best
moment to administer OKT3 would be six hours following
administration of steroids, when circulating T lymphocytes are
maximally decreased. Since a time interval between MPNS and
OKT3 of one hour was claimed as the most beneficial in the
literature [9, 16], we have chosen this interval as the other
alternative of our study.
Most studies on modulating adverse reactions of treatment with
anti-CD3 mAb by corticosteroids have been performed in mice,
which are known to be steroid sensitive [13, 14]. Data obtained
from those studies cannot be simply extrapolated to humans, who
are a corticosteroid-resistant species [21]. In the two studies
performed in humans on modulating clinical side effects following
OKT3, interpretation of the results was hampered by the concom-
itant effects of anesthesia [9, 16]. Moreover, only time intervals up
to 60 minutes between the administration of MPNS and OKT3
were tested.
The aim of the present study was to modulate the clinical side
effects complicating the first dose of OKT3 by variation of the
time interval between administration of MPNS and OKT3. Three
different groups of renal transplant patients, treated with 5 mg
OKT3 daily for ten consecutive days for acute cellular rejection
were studied. One group received 500 mg MPNS six hours
preceding administration of the first dose of OKT3, one group
received 500 mg MPNS one hour prior to the first dose of OKT3
and one group received the same amount of MPNS but now
divided in two doses of 250 mg, given six hours and one hour prior
to administration of OKT3.
In addition to monitoring of clinical side effects, lymphocyte
numbers were followed in time and plasma TNF, and IL-6 levels
were determined at frequent intervals.
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Methods
Patients
Informed consent was obtained from all patients.
All patients were renal allograft recipients treated for acute
cellular rejection. The diagnosis of acute rejection was made on
clinical grounds and was histologically proven. Basic immunosup-
pressive therapy consisted of cyclosporine in a dosage based on
serum trough levels and prednisolone 10 mg per day. First,
lymphocyte counts following 500 mg MPNS were measured in five
patients treated with a six day course of MPNS once a day. These
patients experienced a second rejection, the former being treated
with OKT3 at least four weeks before. Patients included in the
actual study were all treated with a ten day course of OKT3, 5 mg
once a day intravenously for their first rejection. Before adminis-
tration of OKT3, overhydration was excluded by physical exami-
nation and a chest X-ray. Three different groups of patients were
studied: 10 patients (6 male, 4 female; mean age 47 years, range
29 to 62 years) received 500 mg MPNS six hours prior to
administration of OKT3 (—6 hr group), 10 patients (7 male, 3
female; mean age 47 years, range 37 to 65 years) received 500 mg
MPNS one hour prior to administration of OKT3 (—1 hr group)
and six patients (4 male, 2 female; mean age 46 years, range 38 to
58 years) received two times 250 mg MPNS at six hours and at one
hour before administration of OKT3 respectively (—6/—i hr
group). MPNS was given as an infusion during 20 minutes and
OKT3 was administered as a bolus injection. As is common in our
department, all patients were also given 25 mg promethazine
orally one hour before OKT3 administration.
Clinical parameters
Body temperature was measured orally prior to the first admin-
istration of OKT3 and 2, 4, 8, 12, 24, 36, and 48 hours afterwards.
Side effects were assessed in the following way: each patient was
observed and questioned for the presence of (1) chills, (2) fever>
38.5, (3) dyspnoea, (4) vomiting or nausea (5) diarrhea, and (6)
headache in the time intervals ranging from 0 to 3 hours, 3 to 6
hours, 6 to 12 hours, 12 to 24 hours, 24 to 36 hours and 36 to 48
hours after the administration of OKT3. Each positive symptom,
when present during a certain time interval, was graded one point.
In this way, the maximum side effect score in a given time interval
was 6.
Blood pressure was taken manually, twice a day at 8:00 a.m. and
at 3:00 p.m.
Blood sampling
Venous blood samples were drawn just prior to MPNS, prior to
the first OKT3 administration and 30, 60, 120, 180, 240, 720 and
1440 minutes afterwards. Total leukocyte and differential counts
were determined by flow cytometly (Technicon Hi system, Tech-
nicon Instruments, Tariytown, New York, USA).
After immediate centrifugation of the blood samples, plasma
was stored at —70°C. In order to avoid interassay variation, all
samples obtained from each single individual were thawed later
on and assayed in the same experiment. Plasma TNF-a levels
were determined with a commercially available ELISA (Medge-
nix, Billerica, Massachusetts, USA). IL-6 levels were determined
by ELISA as has been described previously [221. The lower limit
of detection of the TNF assay was 5 pglml, and of the IL-6 assay
10 pg/mI.
Table 1. Body temperature in °C (median and 95% confidence
interval) of the three groups studied at different time points after the
first OKT3 administration
Time (hours)
after OKT3
administration —6 hr group —i hr group
—6/—i hr
group
0
2
4
8
12
24
36 (36—37)
373 (36°—38°)
38° (374_386)
386 (379390)
394 (38—39)
38° (373_386)
372 (367_378)
38 (384_392)
38 (38°—39)
382 (377_391)
379 (374_382)
373 (36—38')
366 (363_368)
36 (35—38°)
373 (364_381)
370 (362_379)
378 (36—38)
371 (362_385)
Statistical analysis
Values are expressed as the median and 95% confidence
interval (95% CI) of each group. Although actual values of all
parameters varied considerably as reflected by the big range, the
kinetics of these parameters of each individual patient of the same
group were comparable. Statistical analysis was performed with
the Wilcoxon signed ranks test and the Mann Whitney test as
indicated in the text. A probability (P) value < 0.05 was consid-
ered to be significant.
Results
Lymphocyte counts in patients treated with 500 mg MPNS only
Lymphocyte counts decreased to 60% of pretreatment values
(95% C.!. 42 to 77%) at one hour following MPNS infusion (P =
0.0431, Wilcoxon signed ranks test) and to 37% (95% C.!. 27 to
47% ) at six hours following MPNS administration (P = 0.0431,
Wilcoxon signed ranks test). The difference between one and six
hours after administration of MPNS was not significant.
Patients treated with OKT3
Body temperature. Table 1 and Figure 1 (for clear visualization
of body temperature kinetics) show the median body temperature
of the three groups studied, which did not show a significant
difference before OKT3 administration. In the —1 hr group body
temperature reached 389°C (95% CI, 38 to 392°C) at two hours
after OKT3. In the —6 hr group body temperature increased to
394°C (95% CI, 38° to 39°°C) at 12 hours following OKT3. In the
—6/—i hr group temperature rose to a maximum of 378°C only
(95% CI, 36 to 388°C). Peak temperature levels were significantly
decreased in the —6/—i hr group as compared to the —6 and the
—i hr group (Mann Whitney P = 0.0459 and P = 0.0157,
respectively). On the day following the second administration of
OKT3 peak body temperature in the —1 hr group, —6 hr group
and —6/—i hr group were 38°°C (95% CI, 374 to 39°°C), 388°C
(95% CI, 38° to 396°C) and 384°C (95% CI, 36 to 394°C),
respectively. These data were statistically not different.
Side effects. Side effect scores of the three groups are depicted
in Figure 2. Peak side effects score in the —i hr group was 3.0
(95% CI, 1.8 to 4.0), in the —6 hr group 3.0 (95% CI, 1.5 to 3.4)
and in the —6/—i hr group 1.0, (95% CI 0.4 to 1.6). Peak side
effects were significantly decreased in the —6/—i hr group as
compared to the —6 and —1 hr group (Mann Whitney P =0.0392
and 0.016, respectively). All patients in the —6/—i hr group had
chills one hour after administration of OKT3, followed by a
relatively uneventful period. There were no significant differences
between the —6 hour and the —i hour groups. On the day after
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OKT3
administration
—6 hr group
first second
—1 hr
first
group
second
—6/—i h
first
r group
second
Patient
1 7.00 am 150/100 140/100 140/70 125/70 140/85 140/85
3.00 pm 150/90 110/65 160/80 140/65 145/90 115/80
2 7.00 am 115/75 105/60 140/90 130/80 160/110 125/75
3.00 pm 110/75 110/75 115/60 115/65 125/85 120/80
3 7.00 am 130/85 130/80 140/100 150/110 140/95 130/90
3.00 pm 130/85 100/50 125/80 170/95 160/80 145/80
4 7.00 am 180/110 150/90 160/100 150/100 120/70 130/70
3.00 pm 120/75 110/90 150/95 155/100 150/80 120/80
5 7.00 am 140/80 140/80 120/100 130/70 125/80 110/70
3.00 pm 125/75 125/75 110/90 125/60 140/80 140/90
6 7.00 am 165/90 130/75 180/95 140/90 125/80 110/80
3.00 pm 140/70 130/75 160/100 160/100 115/80 105/70
7 7.00 am 170/100 140/80 140/90 140/100
3.00 pm 160/90 160/95 135/95 95/70
8 7.00 am 150/90 160/90 160/90 120/70
3.00 pm 170/100 150/90 130/80 140/75
9 7.00 am 120/90 100/70 120/80 125/80
3.00 pm 100/70 110/70 130/80 125/80
10 7.00 am 140/80 130/80 160/95 150/80
3.00 pm 130/80 140/90 155/90 165/90
109/liter (95% CI, 0.41 to 0.94 x 109/Iiter) to 0.48 X 109/liter (95%
CI, 0.31 to 0.73 X 109/Iiter) and from 0.71 X 109/liter (95% CI,
0.38 to 1.0 X 109/liter) to 0.34 x 109/liter (95% CI, 0.26 to 0.54 X
109/liter) in the —6 hr, —1 hr and the —6/—i hr groups, respec-
tively. There was no significant difference between the absolute
numbers of circulating T cells of the three groups just prior to
OKT3 treatment.
IL-6 and TNF. Plasma levels of IL-6 and TNF of the three
groups studied are depicted in Figure 3. Serum IL-6 levels in the
—1 hr group increased to 43 pg/mI (95% CI, 7 to 230 pg/ml), in the
—6 hr group to 180 pg/mI (95% CI, 5 to 4097), and in the —6/—i
hr group to 14 (95% CI, 5 to 37). Peak serum IL-6 levels were
______
significantly decreased in the —6/—i hr group as compared to the
—6 hr group (Mann Whitney P = 0.0152), but not as compared to
12—24 the —1 hr group (Mann Whitney P = 0.153). Peak IL-6 levels in
both the —1 hr group and the —6/—i hr group appeared three
hours following administration of OKT3. Peak IL-6 levels in the
—6 hr group appeared to be postponed for three hours. Serum
TNF levels in the —1 hr group increased to 1050 pg/mi (95% CI,
755 to 1511 pg/ml), in the —6 hr group to 433 pg/ml (95% CI, 199
to 907 pg/ml) and in the —6/—i hr group to 559 pg/ml (95% CI,
283 to 942 pg/ml). The —1 hr group experienced significantly
higher TNF levels as compared to the —6 hr and the —6/—i hr
groups (P = 0.0321, Mann Whitney).
Discussion
Since the use of OKT3 as an immunosuppressive agent, several
therapeutic interventions have been tried to reduce adverse
reactions in man, among which pretreatment with indomethacin
[23, 24], pentoxyrlline [25] and mAb anti-TNF [26]. In all these
studies corticosteroids were also administered in different dosages
ranging from 1 mg/kg to 500 mg simultaneously with, or one to
two hours before the first OKT3 injection. Up to now, none of the
tested approaches could totally prevent side effects complicating
therapy with mAb anti-CD3.
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Table 2. Blood pressure following the first and second administration
of OKT3
0
1'
36.5 -
0 4 8 12 16 20 24
0KT3 Time, hours
Fig. 1. Body temperature during the first day following administration of
OKT3. Results are represented as medians in each group. Symbols are:
(0) —1 hr group; (•) —6 hr group; (U) —i/—6 hr group.
1.0
0.0
0—3
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Fig. 2. Clinical side effects score plotted against time. Results are repre-
sented as medians in each group. Symbols are: (0) —1 hr group; (•) —6
hr group; (•) —1/—6 hr group.
the second OKT3 administration, peak side effects score in the —1
hr group, —6 hr group and —1/—6 hr group were 1(95% CI, 0.51
to 1.71), 2 (95% CI, 0.88 to 2.2) and 1 (95% CI, 0.22 to 2.7),
respectively. These differences were not significant.
Blood pressures in the three groups remained essentially un-
changed, following the first and second OKT3 administration
(Table 2).
3-6 6—i 2
Absolute lymphocyte counts. Corticosteroids reduced the abso-
lute number of T lymphocytes in all three groups significantly
from 0.79 x 109/liter (95% CI, 0.59 to 1.44 X 109/liter) before the
administration of MPNS to 0.49 X 109/liter (95% CI, 0.42 to 0.62
x 109/liter) before the administration of OKT3: from 0.67 x
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when given one hour prior to OKT3, than when MPNS and OKT3
were given concomitantly [16]. However, in that study the late
clinical side effects and cytokine levels also might be affected by
anesthesia, which was performed in all patients four to eight hours
following OKT3 administration. Regarding the efficacy of differ-
ent doses of corticosteroids, one study has been performed in
renal transplant patients, treated prophylactically with OKT3 [271.
This study showed a more pronounced decrease in serum TNF
and IFN-'y release, when these patients were pretreated with
MPNS in a high dosage (8 mg/kg) than in a low dosage (1 mg/kg)
both being administered at four hours prior to OKT3. However,
they did not observe any difference neither in occurrence nor in
severity of clinical side effects in either of the two groups.
In the present study we demonstrate a clear beneficial effect of
corticosteroids when administered in two divided doses of each
250 mg at six hours and at one hour preceding the first dose of
OKT3.
We initially hypothesized that administration of OKT3 at the
nadir of circulating mononuclear blood cells would reduce clinical
side effects. Previous studies have shown that oral administration
of 10, 30 and 60 mg prednisolone to healthy individuals induces
lymphocytopenia with a nadir at six hours after intake of pred-
nisolone [19]. Prior to the onset of this study, we studied
peripheral blood lymphocyte kinetics in five renal transplant
recipients treated for acute rejection with 500 mg MPNS. One
hour after the administration of MPNS, absolute counts of
circulating lymphocytes were significantly decreased. Six hours
following administration of MPNS lymphocyte numbers were
even more decreased as compared to one hour after MPNS
administration. Although this difference reached no significance,
we assumed that the optimal time interval between the adminis-
tration of MPNS and OKT3 would be six hours. The more so as
previous data from the literature show that prednisolone affects
CD4-positive lymphocytes more than CD8-positive lymphocytes,
resulting in a decline of CD4/CD8 ratio maximally at six hours
after administration of prednisolone [19] and since a positive
correlation between CD4 cells and clinical side effects has been
found [10]. In agreement with the above-described findings we
found that absolute numbers of circulating lymphocytes between
the three groups—although significantly decreased as compared
to levels prior to administration of MPNS— did not differ signif-
icantly just before administration of OKT3.
The results of the present study do not support our initial
hypothesis. We could not detect an advantage of administration of
corticosteroids six hours prior to OKT3 above the administration
of corticosteroids one hour prior to OKT3 regarding either
plasma levels of IL-6, body temperature or side effect score.
Apparently steroid-induced circulating lymphocytopenia has no
major effect on adverse reactions after the first administration of
OKT3. This may be explained by the fact that steroids probably
hduce margination of circulating lymphocytes but have no influ-
ence on the total body lymphocyte burden [28]. Circulating
lymphocytes numbers after the administration of MPNS may not
be representative of total body lymphocyte counts, whereas in a
"steady state"—as in the patient groups studied by Gaston et
al—they may.
However, because of the observations in both groups (—6 hr;— 1
hr) we could indeed demonstrate an additive beneficial effect on
A
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Fig. 3. Serum 11-6 levels (A) and serum TNF levels (B) plotted against time.
Results are represented as medians in each group. Symbols are: (0) —1 hr
group; (•) —6 hr group; () —11—6 hr group.
Regarding pretreatment with corticosteroids, several doses and
time points have been evaluated. In mice, administration of
corticosteroids just prior to the administration of a hamster
anti-CD3 mAb protected them from hypothermia, renal tubular
necrosis and fatty infiltration of the liver and almost completely
inhibited release of TNF and IL-6 [13]. However, these effects
were most impressive when steroids were administered in a
dosage of 50 mg/kg, three hours before the anti CD3 mAb was
injected. In this study other doses and time intervals were not
tested. Ferran et al reported a beneficial effect of a single dose of
1 mg hydrocortisone on hypothermia, diarrhea and release of
IFN-y, TNF and IL-6 in mice, when administered one hour before
infusion of the anti-CD3 mAb compared to simultaneous admin-
istration. These authors stated that steroids, when given more
than one hour prior to anti-CD3, were ineffective [14]. A random-
ized pilot study in renal transplant recipients receiving OKT3
prophylactically showed a greater salutary effect of 500 mg MPNS
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all parameters of administration of corticosteroids in two divided
doses at —6 and —1 hr, respectively.
Obviously, mechanisms other than a reduced absolute periph-
eral lymphocyte count have a role. Explanations for the observed
findings may be deduced from data obtained from experiments
both in vitro [29—33] and in vivo [34]. Corticosteroids are known to
inhibit the production of TNF by LPS-stimulated human mono-
cytes in a dose and time dependent manner; maximum inhibition
was achieved when monocytes were preincubated with corticoste-
roids during 48 hours. Less inhibition was observed when incuba-
tion time was shortened [29]. Others demonstrated inhibition of
the transcription and translation of mRNA for TNF by dexameth-
asone [30]. Moreover, incubation of a myelomonocytic cell line
(U937) with corticosteroids during 48 hours reduced transcription
of mRNA of FcRI and FcRII and decreased surface expression of
FcyR [31]. These receptors have a role in activation of monocytes
and consequently in the triggering of release of TNF and IL-6
[32]. Hydrocortisone also inhibits IL-6 synthesis by LPS-stimu-
lated human peripheral blood mononuclear cells [33].
In our study, decreased TNF peak levels after OKT3 adminis-
tration correlated well with an abrogated pyrogen response in the
first few hours following OKT3, but less with other clinical side
effects. This suggests that at least other mediators of the cytokine
network or other mechanisms, such as activation of neutrophilic
granulocytes, play a role in the generation of adverse reactions
[12].
The decreased plasma TNF level in the —6 hr group compared
to that in the —1 hr group is in agreement with results of others
[34], who found lower TNF levels and unchanged IL-6 levels
following LPS infusion in human volunteers, providing LPS
infusion was preceded by corticosteroids administered by contin-
uous infusion during six hours. When steroid infusion was fol-
lowed by an interval of six hours prior to LPS, there was no
difference between clinical side effects compared to the group who
received LPS alone, but TNF levels remained decreased and IL-6
levels even increased.
Our patients in the —6 hr group had peak IL-6 levels after 6
hours, and peak body temperature 12 hours after administration
of OKT3. Indeed, a delay of four hours between IL-6 administra-
tion and a systemic reaction has been reported [35].
We realize that patients in our study were not randomly
assigned to the different groups and that this easily can introduce
bias, especially regarding clinical side effects. However, we think
that we still may draw conclusions from our findings since the
other parameters (body temperature, serum TNF and IL-6 levels)
support the data concerning the adverse reactions. Body temper-
ature and cytokine levels are not liable to bias.
Despite pretreatment with steroids, first dose effects were still
seen. Alternate approaches or additional treatment such as ad-
ministration of anti-TNF or anti-IFNy mAbs may be of supple-
mentary value in reducing adverse reactions after OKT3 [36, 37].
We conclude that two doses of 250 mg MPNS administered six
hours and one hour before the first administration of OKT3
effectively, although not completely, prevents clinical side effects.
This regimen is superior to administration of the same amount of
steroids in one dose either one hour or six hours before the
administration of OKT3. Beneficial effects of divided steroid
administration on clinical side effects were mainly apparent on the
first day following OKT3 administration.
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